{"nctId":"NCT00549718","briefTitle":"Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia","startDateStruct":{"date":"2007-10"},"conditions":["Schizophrenia"],"count":489,"armGroups":[{"label":"Lurasidone 40mg","type":"EXPERIMENTAL","interventionNames":["Drug: Lurasidone HCl"]},{"label":"Lurasidone 80mg","type":"EXPERIMENTAL","interventionNames":["Drug: Lurasidone HCl"]},{"label":"Lurasidone 120mg","type":"EXPERIMENTAL","interventionNames":["Drug: Lurasidone HCl"]},{"label":"Sugar Pill","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Lurasidone HCl"]}],"interventions":[{"name":"Lurasidone HCl","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nTo be eligible to enter the study, each patient must comply with the following inclusion criteria:\n\n* Provide written informed consent and aged between 18 and 75 years of age.\n* Meets DSM-IVâ„¢ criteria for a primary diagnosis of schizophrenia.\n* Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.\n* Able and agrees to remain off prior antipsychotic medication for the duration of study.\n* Good physical health on the basis of medical history, physical examination, and laboratory screening.\n* Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.\n\nExclusion Criteria:\n\n* Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.\n* Any chronic organic disease of the CNS (other than schizophrenia)\n* Used investigational compound within 30 days.\n* Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"CGI-S From Baseline to the End of the Double-blind Treatment","description":"Clinical Global Impression of Severity is a clinician-rated assessment of the subject's current illness state on a 7 point scale, where a higher score is associated with greater illness severity. The scale has a single item measured on a 7 point scale from 1 ('normal', not ill) to 7 (extremely ill).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":null},{"groupId":"OG001","value":"-1.4","spread":null},{"groupId":"OG002","value":"-1.2","spread":null},{"groupId":"OG003","value":"-1.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Total PANSS Score From Baseline to the End of the Double Blind Phase","description":"The PANSS is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.2","spread":null},{"groupId":"OG001","value":"-23.4","spread":null},{"groupId":"OG002","value":"-20.5","spread":null},{"groupId":"OG003","value":"-17.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":124},"commonTop":["Akathisia","Headache","Somnolence","Nausea","Sedation"]}}}